An implant for sleep apnea is one of the few CPAP alternatives. This article compares hypoglossal nerve stimulation and ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...

For years, Michelle Strickland had trouble sleeping – she woke up several times at night - and it left her with daytime ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

My wife, who bore the brunt of my transformation into a grumpy badger, was the first to suggest I get a sleep study. She’d ...

According to statistics by the American Association of Medicine, the disorder sleep apnea affects approximately 30 million US ...

This represents an acceleration of cost growth after the prior three quarters ... impact of GLP-1 weight-loss drugs on obstructive sleep apnea (‘OSA’) prevalence, and the negative influence ...

The global anti-snoring devices market, valued at US$ 0.83 billion in 2023, is forecasted to grow at a robust CAGR of 9.8%, reaching US$ 0.91 ...

Most anti-snoring products won't be a permanent treatment for moderate to severe sleep apnea, but CPAP machines are still the gold standard for treatment. But if you're a mild snorer with no ...